Mostrar el registro sencillo del ítem
Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults
dc.contributor.author | Allen, Claire | |
dc.date.accessioned | 2020-04-25T00:45:02Z | |
dc.date.available | 2020-04-25T00:45:02Z | |
dc.date.issued | 2020-03-22 | |
dc.identifier.uri | https://www.evidenceaid.org/short-course-versus-prolonged-course-antibiotic-therapy-for-hospital-acquired-pneumonia-in-critically-ill-adults/ | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1213 | |
dc.description.abstract | Citation: Pugh R, Grant C, Cooke RPD, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database of Systematic Reviews 2015; (8): CD007577 What is this? Some patients with COVID-19 will become critically ill and need to be treated in an intensive care unit (ICU). Pneumonia is the most common hospital-acquired infection, particularly affecting patients in the ICU. Antibiotic courses of different lengths are used to treat it. In this Cochrane systematic review, the authors searched for randomized trials comparing a ‘short’ duration of antibiotic therapy versus a ‘prolonged’ course for hospital-acquired pneumonia in critically ill adults, including those on mechanical ventilation who might develop ventilator-acquired pneumonia (VAP). They did not restrict by date or language of publication and did their searches in June 2015. They identified 6 eligible studies (1088 participants), but with substantial variation in how the included patients’ pneumonia was diagnosed or defined. What works: For patients with VAP, courses of antibiotics lasting 7 or 8 days increase the number of antibiotic‐free days in the 4 weeks after treatment and reduce the recurrence of pneumonia compared with courses lasting 10 to 15 days, without increasing mortality or other recurrence outcomes. What doesn’t work: For patients with VAP specifically due to non‐fermenting Gram‐negative bacilli (NF‐GNB), recurrence was greater after 8-day courses compared to courses lasting 10 to 15 days, but mortality outcomes were not significantly different. What’s uncertain: Nothing noted. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Iatrogenic Disease | en_US |
dc.subject | Pneumonia | en_US |
dc.title | Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults | en_US |
eihealth.country | Others | en_US |
eihealth.category | Clinical characterization and management | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Evidence Aid | en_US |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |